AREV Life Sciences Global Corp. (AREVF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AREV Life Sciences Global Corp. (AREVF) with AI Score 43/100 (Weak). AREV Life Sciences Global Corp. focuses on developing and selling functional ingredients, particularly CBD-infused products, targeting the natural health and nutraceutical markets. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026AREV Life Sciences Global Corp. (AREVF) Healthcare & Pipeline Overview
AREV Life Sciences Global Corp. is a Canadian integrated life science company producing and distributing functional ingredients, including CBD-infused products and nutraceutical formulations, targeting the natural health, medical, and sports nutrition markets. The company focuses on addressing health issues such as sleep deprivation, anxiety, and pain management through its diverse product line.
Investment Thesis
AREV Life Sciences Global Corp. operates in the growing market for functional ingredients and CBD-infused products. The company's diverse product line targeting various health conditions presents a potential growth opportunity. However, the company's negative profit margin of -2940.4% and gross margin of -155.7% raise concerns about its financial sustainability. The high beta of 5.40 indicates significant volatility relative to the market. Key growth catalysts include expanding its product distribution and market reach. Investors should carefully consider the company's financial performance and market competition before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a small company with limited resources.
- P/E Ratio of -1.87 suggests the company is not currently profitable.
- Profit Margin of -2940.4% indicates significant losses relative to revenue.
- Gross Margin of -155.7% shows the company's cost of goods sold exceeds its revenue.
- Beta of 5.40 suggests the stock is highly volatile compared to the market.
Competitors & Peers
Strengths
- Diverse product line targeting various health conditions.
- Proprietary formulations for CBD-infused products.
- Established presence in the Canadian market.
- Offers white-label manufacturing services.
Weaknesses
- Negative profit margin and gross margin.
- High beta indicating significant volatility.
- Limited market capitalization.
- Dependence on the Canadian market.
Catalysts
- Upcoming: Potential expansion into new geographic markets, such as the United States and Europe, by the end of 2026.
- Ongoing: Continued development and launch of new CBD-infused products and nutraceutical formulations.
- Ongoing: Strategic partnerships with distributors and other companies in the health and wellness industry.
- Upcoming: Potential acquisitions of companies with complementary product lines or technologies by Q4 2026.
Risks
- Ongoing: Intense competition in the nutraceutical and CBD markets could limit AREV's market share and profitability.
- Ongoing: Regulatory hurdles and changing regulations could impact the company's ability to market and sell its products.
- Potential: Fluctuations in the price of raw materials could increase the company's cost of goods sold and reduce its profit margins.
- Potential: Product recalls or liability claims could damage the company's reputation and financial performance.
- Ongoing: The company's negative profit margin and gross margin raise concerns about its financial sustainability.
Growth Opportunities
- Expansion into New Geographies: AREV can pursue growth by expanding its distribution network beyond Canada into other regions, such as the United States and Europe, where the market for CBD-infused products and nutraceuticals is growing. This expansion could involve establishing partnerships with local distributors or setting up its own distribution channels. The global nutraceuticals market is expected to reach $441.7 billion by 2026, providing a substantial opportunity for AREV to increase its revenue base.
- Product Line Diversification: AREV can diversify its product line by developing new formulations and delivery methods for its functional ingredients. This could include creating new CBD-infused products, such as beverages, edibles, and topical creams, as well as expanding its range of nutraceuticals and therapeutic food products. By offering a wider variety of products, AREV can attract a broader customer base and increase its market share. The market for CBD-infused beverages alone is projected to reach $1.4 billion by 2028.
- Strategic Partnerships and Acquisitions: AREV can pursue growth through strategic partnerships and acquisitions. This could involve partnering with other companies in the health and wellness industry to expand its distribution network or acquiring companies with complementary product lines or technologies. Strategic acquisitions can provide AREV with access to new markets, technologies, and expertise, accelerating its growth and enhancing its competitive position. The mergers and acquisitions activity in the pharmaceutical and nutraceutical sectors remains robust, offering various opportunities for AREV.
- Focus on Research and Development: AREV can invest in research and development to develop new and innovative products that address unmet needs in the market. This could involve conducting clinical trials to demonstrate the efficacy of its products or developing new formulations with enhanced bioavailability and therapeutic effects. By focusing on research and development, AREV can differentiate itself from its competitors and create a sustainable competitive advantage. The global investment in pharmaceutical R&D is projected to reach $238 billion by 2028.
- White Label and Private Label Opportunities: AREV can leverage its manufacturing capabilities to offer white-label and private-label services to other companies in the health and wellness industry. This could involve producing CBD-infused products, nutraceuticals, and therapeutic food products for other brands to sell under their own labels. By offering white-label and private-label services, AREV can generate additional revenue streams and increase its capacity utilization. The global white-label market is projected to reach $8.5 billion by 2027.
Opportunities
- Expansion into new geographies, such as the United States and Europe.
- Product line diversification with new formulations and delivery methods.
- Strategic partnerships and acquisitions.
- Focus on research and development to develop innovative products.
Threats
- Intense competition in the nutraceutical and CBD markets.
- Regulatory hurdles and changing regulations.
- Fluctuations in the price of raw materials.
- Potential for product recalls or liability claims.
Competitive Advantages
- Proprietary formulations for CBD-infused products.
- Established presence in the Canadian market.
- Diverse product line targeting various health conditions.
- Manufacturing capabilities for white-label production.
About AREVF
AREV Life Sciences Global Corp., established in 2005 and based in Coquitlam, Canada, operates as an integrated life science discovery company focused on the production and sale of functional ingredients. Originally incorporated as AREV NanoTec Brands Inc., the company rebranded in August 2021 to reflect its broader focus on life sciences. AREV specializes in CBD-infused products, including Canna-Mulsion and NaturVax anti-viral supplements, NaturRelax for sleep aid, and Natur Relief for pain and inflammation. The company also offers white-label cannabis products, THC products, cannabis skincare, medicinal oils, and edibles. These ingredients are designed for use in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. AREV's product line addresses various health concerns, including sleep deprivation, insomnia, anxiety, pain, and inflammatory conditions. Additionally, AREV provides nutraceutical product formulations under the Bare brand and ready-to-use therapeutic food products under the SUS-TAINN brand, expanding its reach in the health and wellness sector.
What They Do
- Produces and sells functional ingredients.
- Develops and markets CBD-infused products.
- Offers anti-viral supplements under the NaturVax brand.
- Provides natural sleep aids under the NaturRelax brand.
- Offers anti-inflammatory and pain relief products under the Natur Relief brand.
- Manufactures white-label cannabis products.
- Develops nutraceutical product formulations under the Bare brand.
- Produces ready-to-use therapeutic food products under the SUS-TAINN name.
Business Model
- Develops and manufactures functional ingredients and CBD-infused products.
- Sells products through distributors and direct-to-consumer channels.
- Offers white-label manufacturing services to other companies.
- Generates revenue from the sale of its branded products and white-label services.
Industry Context
AREV Life Sciences Global Corp. operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for nutraceuticals and CBD-infused products. The market is competitive, with companies like AOXG, CNNXF, CWWBF, GBHPF, and GRVE vying for market share. The increasing acceptance of cannabis-based products for medicinal and recreational use is a significant trend, but regulatory hurdles and competition remain challenges. The global nutraceuticals market is projected to reach billions of dollars, offering opportunities for companies like AREV to expand their market presence.
Key Customers
- Consumers seeking natural health and wellness products.
- Distributors of nutraceuticals and functional foods.
- Companies in the natural health, medical, and sports nutrition markets.
- Businesses seeking white-label manufacturing services.
Financials
Chart & Info
AREV Life Sciences Global Corp. (AREVF) stock price: Price data unavailable
Latest News
-
New 52-Week Lows For Monday Morning
· Aug 5, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AREVF.
Price Targets
Wall Street price target analysis for AREVF.
MoonshotScore
What does this score mean?
The MoonshotScore rates AREVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael C. Withrow
CEO
Michael C. Withrow serves as the CEO of AREV Life Sciences Global Corp. His background includes experience in the pharmaceutical and nutraceutical industries. Withrow has held various leadership positions in companies focused on developing and marketing innovative health and wellness products. He brings expertise in product development, regulatory affairs, and market strategy. His focus is on driving AREV's growth through strategic partnerships and product innovation.
Track Record: Under Michael Withrow's leadership, AREV Life Sciences Global Corp. has focused on expanding its product line and market reach. Key achievements include the development of new CBD-infused products and the establishment of partnerships with distributors. The company has also focused on enhancing its manufacturing capabilities and expanding its white-label services. However, the company's financial performance remains a challenge.
AREVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AREV Life Sciences Global Corp. may not meet the minimum financial standards or reporting requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in AREV Life Sciences Global Corp.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier indicates a higher risk of fraud or mismanagement.
- Lack of regulatory oversight increases the potential for market manipulation.
- The company's financial performance raises concerns about its long-term viability.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Determine the company's ownership structure and insider holdings.
- Monitor news and press releases for any red flags or material events.
- Consult with a financial advisor to assess the suitability of the investment.
- The company has been in operation since 2005.
- AREV has a diverse product line targeting various health conditions.
- The company offers white-label manufacturing services.
- AREV has a CEO with experience in the pharmaceutical and nutraceutical industries.
Common Questions About AREVF
What does AREV Life Sciences Global Corp. do?
AREV Life Sciences Global Corp. is an integrated life science discovery company that produces and sells functional ingredients, primarily CBD-infused products, in Canada. The company's product line includes Canna-Mulsion, NaturVax, NaturRelax, and Natur Relief, targeting various health conditions such as sleep deprivation, anxiety, pain, and inflammation. AREV also offers white-label cannabis products, THC products, cannabis skincare, medicinal oils, and edibles. Its ingredients are used in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. Additionally, AREV provides nutraceutical product formulations under the Bare brand and therapeutic food products under the SUS-TAINN name.
What do analysts say about AREVF stock?
There is currently no available analyst coverage or consensus on AREVF stock. Given its OTC listing and small market capitalization, the company may not be widely followed by analysts. Investors should conduct their own independent research and due diligence before investing in AREVF. Key valuation metrics, such as P/E ratio and profit margin, indicate that the company is not currently profitable. Growth considerations include the company's potential to expand its product line and market reach, but these opportunities are subject to various risks and uncertainties.
What are the main risks for AREVF?
The main risks for AREVF include intense competition in the nutraceutical and CBD markets, regulatory hurdles and changing regulations, fluctuations in the price of raw materials, and potential product recalls or liability claims. The company's negative profit margin and gross margin raise concerns about its financial sustainability. As an OTC-listed company, AREVF is subject to less regulatory oversight and may have limited financial disclosure, increasing the risk of fraud or mismanagement. Investors should carefully consider these risks before investing in AREVF.
What are the key factors to evaluate for AREVF?
AREV Life Sciences Global Corp. (AREVF) currently holds an AI score of 43/100, indicating low score. Key strength: Diverse product line targeting various health conditions.. Primary risk to monitor: Ongoing: Intense competition in the nutraceutical and CBD markets could limit AREV's market share and profitability.. This is not financial advice.
How frequently does AREVF data refresh on this page?
AREVF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AREVF's recent stock price performance?
Recent price movement in AREV Life Sciences Global Corp. (AREVF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product line targeting various health conditions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AREVF overvalued or undervalued right now?
Determining whether AREV Life Sciences Global Corp. (AREVF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AREVF?
Before investing in AREV Life Sciences Global Corp. (AREVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully accurate.
- OTC market investments carry higher risks.
- Analyst coverage is non-existent.